Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
Isla, Dolores, De Castro, Javier, Vidal, Oscar Juan, Grau, Santiago, Orofino, Javier, Gordo, Rocío, Rubio-Terrés, Carlos, Rubio-Rodríguez, DaríoVolume:
Volume 9
Language:
english
Journal:
ClinicoEconomics and Outcomes Research
DOI:
10.2147/CEOR.S121093
Date:
December, 2016
File:
PDF, 157 KB
english, 2016